BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16769276)

  • 21. Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
    Salgado J; Zabalegui N; García-Amigot F; Gil MC; González MS; García-Foncillas J
    Oncol Rep; 2005 Jul; 14(1):85-8. PubMed ID: 15944772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.
    Tilanus-Linthorst MM; Bartels KC; Alves C; Bakri B; Crepin E; van den Ouweland A; Klijn JG; Meijers-Heijboer H; Brekelmans CT
    Breast Cancer Res Treat; 2006 Jan; 95(2):117-23. PubMed ID: 16319990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
    Cecener G; Egeli U; Tunca B; Erturk E; Ak S; Gokgoz S; Tasdelen I; Tezcan G; Demirdogen E; Bayram N; Avci N; Evrensel T
    Cancer Invest; 2014 Oct; 32(8):375-87. PubMed ID: 24884828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
    Beetstra S; Salisbury C; Turner J; Altree M; McKinnon R; Suthers G; Fenech M
    Carcinogenesis; 2006 Mar; 27(3):517-24. PubMed ID: 16162645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
    Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
    Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 and BRCA2 in Indian breast cancer patients.
    Saxena S; Szabo CI; Chopin S; Barjhoux L; Sinilnikova O; Lenoir G; Goldgar DE; Bhatanager D
    Hum Mutat; 2002 Dec; 20(6):473-4. PubMed ID: 12442273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
    Verhoog LC; Berns EM; Brekelmans CT; Seynaeve C; Meijers-Heijboer EJ; Klijn JG
    J Clin Oncol; 2000 Nov; 18(21 Suppl):119S-24S. PubMed ID: 11060339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
    Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
    Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
    Haffty BG; Harrold E; Khan AJ; Pathare P; Smith TE; Turner BC; Glazer PM; Ward B; Carter D; Matloff E; Bale AE; Alvarez-Franco M
    Lancet; 2002 Apr; 359(9316):1471-7. PubMed ID: 11988246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.
    Capalbo C; Ricevuto E; Vestri A; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Eur J Hum Genet; 2006 Jan; 14(1):49-54. PubMed ID: 16288312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
    Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
    Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues.
    Larson PS; Schlechter BL; de las Morenas A; Garber JE; Cupples LA; Rosenberg CL
    J Clin Oncol; 2005 Dec; 23(34):8613-9. PubMed ID: 16314623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
    Phillips KA
    J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pregnancy and risk of early breast cancer in patients sith BRCA1 and BRCA2 mutations].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2000 Jul; 176(7):335-6. PubMed ID: 10963002
    [No Abstract]   [Full Text] [Related]  

  • 39. Are local recurrences after breast conserving therapy more frequent in patients with BRCA1/BRCA2 mutations?
    Kurtz JM
    Strahlenther Onkol; 2000 Sep; 176(9):433-4. PubMed ID: 11050918
    [No Abstract]   [Full Text] [Related]  

  • 40. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
    Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
    Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.